Among collagen members in the collagen superfamily,type XIX collagen has raised increasing interest in relation to its structural and biological roles.Type XIX collagen is a Fibril-Associated Collagen with Interrupted...Among collagen members in the collagen superfamily,type XIX collagen has raised increasing interest in relation to its structural and biological roles.Type XIX collagen is a Fibril-Associated Collagen with Interrupted Triple helices member,one main subclass of collagens in this superfamily.This collagen contains a triple helix composed of three polypeptide segments aligned in parallel and it is associated with the basement membrane zone in different tissues.The molecular structure of type XIX collagen consists of five collagenous domains,COL1 to COL5,interrupted by six non-collagenous domains,NCI to NC6.The most relevant domain by which this collagen exerts its biological roles is NCI domain that can be cleavage enzymatically to release matricryptins,exerting anti-tumor and anti-angiogenic effect in murine and human models of cancer.Under physiological conditions,type XIX collagen expression decreases after birth in different tissues although it is necessary to keep its basal levels,mainly in skeletal muscle and hippocampal and telencephalic interneurons in brain.Notwithstanding,in amyotrophic lateral sclerosis,altered transcript expression levels show a novel biological effect of this collagen beyond its structural role in basement membranes and its anti-tumor and anti-angiogenic properties.Type XIX collagen can exert a compensatory effect to ameliorate the disease progression under neurodegenerative conditions specific to amyotrophic lateral sclerosis in transgenic SOD1 G93 A mice and amyotrophic lateral sclerosis patients.This novel biological role highlights its nature as prognostic biomarker of disease progression in and as promising therapeutic target,paving the way to a more precise prognosis of amyotrophic lateral sclerosis.展开更多
目的探究益肾化湿颗粒联合复方α-酮酸治疗非透析慢性肾脏病的临床疗效。方法选取2021年7月—2024年7月香港中文大学(深圳)第二附属医院86例非透析慢性肾脏病患者,根据使用药物方案差异将患者分为对照组和治疗组,每组各43例。对照组口...目的探究益肾化湿颗粒联合复方α-酮酸治疗非透析慢性肾脏病的临床疗效。方法选取2021年7月—2024年7月香港中文大学(深圳)第二附属医院86例非透析慢性肾脏病患者,根据使用药物方案差异将患者分为对照组和治疗组,每组各43例。对照组口服复方α-酮酸片,5片/次,3次/d,进餐时用药。治疗组在对照组治疗基础上口服益肾化湿颗粒,1袋/次,3次/d,温水冲服。两组均连续治疗4个月。观察两组的临床疗效和临床症状消失时间,比较两组肾功能指标、肠道菌群、运动耐力和疲乏相关指标的变化情况。结果治疗后,治疗组总有效率是86.05%,显著高于对照组的67.44%(P<0.05)。治疗过程中,治疗组水肿消退时间、多尿消失时间、血尿消失时间及腰痛消失时间均显著短于对照组(P<0.05)。治疗后,两组血肌酐(Scr)、尿酸(UA)、血尿素氮(BUN)、24 h尿蛋白定量(24 h Upro)均较同组治疗前显著降低(P<0.05);且治疗后,治疗组肾功能指标低于对照组(P<0.05)。治疗后,两组大肠杆菌均较治疗前显著降低,而粪肠球菌、双歧杆菌、乳酸杆菌显著升高(P<0.05);且治疗后,治疗组肠道菌群改善优于对照组(P<0.05)。治疗后,两组无氧阈(AT)、峰值摄氧量(VO_(2)peak)、峰值氧脉搏(VO_(2)/HRpeak)均显著高于治疗前,而运动耐力指标、慢性病治疗功能评估-疲劳量表(FACIT-F)评分低于治疗前,且治疗组运动耐力指标、FACIT-F评分改善优于对照组(P<0.05)。结论益肾化湿颗粒联合复方α-酮酸治疗能增加非透析慢性肾脏病患者获益,缓解临床症状,改善肾功能和运动耐力,纠正肠道菌群失衡,减轻疲乏,安全性较高。展开更多
基金supported by Institutode Salud Carlos Ⅲ(Grant PI17/00949)Fondo Europeode Desarrollo Regional(FEDER)“Una manera de hacer Europa” from the European Union+1 种基金Centrode Investigación Biomédicaen Redsobre Enfermedades Neurodegenerativas(CIBERNED-612)Fundación FEDER(Federación Espa?olade Enfermedades Raras),Consolidated Groupsfrom Gobiernode Aragón
文摘Among collagen members in the collagen superfamily,type XIX collagen has raised increasing interest in relation to its structural and biological roles.Type XIX collagen is a Fibril-Associated Collagen with Interrupted Triple helices member,one main subclass of collagens in this superfamily.This collagen contains a triple helix composed of three polypeptide segments aligned in parallel and it is associated with the basement membrane zone in different tissues.The molecular structure of type XIX collagen consists of five collagenous domains,COL1 to COL5,interrupted by six non-collagenous domains,NCI to NC6.The most relevant domain by which this collagen exerts its biological roles is NCI domain that can be cleavage enzymatically to release matricryptins,exerting anti-tumor and anti-angiogenic effect in murine and human models of cancer.Under physiological conditions,type XIX collagen expression decreases after birth in different tissues although it is necessary to keep its basal levels,mainly in skeletal muscle and hippocampal and telencephalic interneurons in brain.Notwithstanding,in amyotrophic lateral sclerosis,altered transcript expression levels show a novel biological effect of this collagen beyond its structural role in basement membranes and its anti-tumor and anti-angiogenic properties.Type XIX collagen can exert a compensatory effect to ameliorate the disease progression under neurodegenerative conditions specific to amyotrophic lateral sclerosis in transgenic SOD1 G93 A mice and amyotrophic lateral sclerosis patients.This novel biological role highlights its nature as prognostic biomarker of disease progression in and as promising therapeutic target,paving the way to a more precise prognosis of amyotrophic lateral sclerosis.
文摘目的探究益肾化湿颗粒联合复方α-酮酸治疗非透析慢性肾脏病的临床疗效。方法选取2021年7月—2024年7月香港中文大学(深圳)第二附属医院86例非透析慢性肾脏病患者,根据使用药物方案差异将患者分为对照组和治疗组,每组各43例。对照组口服复方α-酮酸片,5片/次,3次/d,进餐时用药。治疗组在对照组治疗基础上口服益肾化湿颗粒,1袋/次,3次/d,温水冲服。两组均连续治疗4个月。观察两组的临床疗效和临床症状消失时间,比较两组肾功能指标、肠道菌群、运动耐力和疲乏相关指标的变化情况。结果治疗后,治疗组总有效率是86.05%,显著高于对照组的67.44%(P<0.05)。治疗过程中,治疗组水肿消退时间、多尿消失时间、血尿消失时间及腰痛消失时间均显著短于对照组(P<0.05)。治疗后,两组血肌酐(Scr)、尿酸(UA)、血尿素氮(BUN)、24 h尿蛋白定量(24 h Upro)均较同组治疗前显著降低(P<0.05);且治疗后,治疗组肾功能指标低于对照组(P<0.05)。治疗后,两组大肠杆菌均较治疗前显著降低,而粪肠球菌、双歧杆菌、乳酸杆菌显著升高(P<0.05);且治疗后,治疗组肠道菌群改善优于对照组(P<0.05)。治疗后,两组无氧阈(AT)、峰值摄氧量(VO_(2)peak)、峰值氧脉搏(VO_(2)/HRpeak)均显著高于治疗前,而运动耐力指标、慢性病治疗功能评估-疲劳量表(FACIT-F)评分低于治疗前,且治疗组运动耐力指标、FACIT-F评分改善优于对照组(P<0.05)。结论益肾化湿颗粒联合复方α-酮酸治疗能增加非透析慢性肾脏病患者获益,缓解临床症状,改善肾功能和运动耐力,纠正肠道菌群失衡,减轻疲乏,安全性较高。
